Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Glaucomatous visual field progression has both personal and societal costs and therefore has a serious impact on quality of life. At the present time, intraocular pressure (IOP) is considered to be the most important modifiable risk factor for glaucoma onset and progression. Reduction of IOP has been repeatedly demonstrated to be an effective intervention across the spectrum of glaucoma, regardless of subtype or disease stage. In the setting of approval of IOP‐lowering therapies, it is expected that effects on IOP will translate into benefits in long‐term patient‐reported outcomes. Nonetheless, the effect of these medications on IOP and their associated risks can be consistently and objectively measured. This helps to explain why regulatory approval of new therapies in glaucoma has historically used IOP as the outcome variable. Although all approved treatments for glaucoma involve IOP reduction, patients frequently continue to progress despite treatment. It would therefore be beneficial to develop treatments that preserve visual function through mechanisms other than lowering IOP. The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria. Nonetheless, these criteria do not take into account the time (and hence, the speed) needed to reach significant change. In this paper we provide an analysis based on the existing literature to support the hypothesis that decreasing the rate of visual field progression by 30% in a trial lasting 12–18 months is clinically meaningful. We demonstrate that a 30% decrease in rate of visual field progression can be reliably projected to have a significant effect on health‐related quality of life, as defined by validated instruments designed to measure that endpoint. HIGHLIGHTSA 30% decrease in rate of visual field progression can be projected to have a significant effect on health‐related quality of life.The US FDA definition of clinically‐meaningful progression corresponds to a slope ≤−0.5 dB/yr in ≥5 abnormal test locations.A 30% decrease in visual field progression with trend analysis is equivalent to a 2–3 mmHg decrease in intraocular pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The number of people with glaucoma worldwide in 2010 and 2020
Quigley, H. A. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.081224 · Cited by 7,394 · cited 1×
“…A 2006 review of worldwide glaucoma prevalence models estimated that by 2010 glaucoma would be the second leading overall cause of blindness in the world and leading cause of irreversible blindness, affecting 60.5 million people with prevalence varying worldwide(Quigley and Broman, 2006) (Error!”
InfluentialGlobal data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Kass, M. A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.701 · Cited by 3,705 · cited 10×
“The Ocular Hypertension Treatment Study (OHTS) compared the effects of IOP-lowering therapy on the risk of OAG development among subjects with statistically high IOP despite normal visual field results and optic nerve head evaluation(Gordon et al., 2002).”
InfluentialHeijl, A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1268 · Cited by 3,320 · cited 19×
“The Early Manifest Glaucoma Trial (EMGT) randomized patients with newly diagnosed glaucoma to treatment and observation arms, confirming the important effect of baseline IOP levels and IOPlowering on progression(Leske et al., 2007).”
InfluentialNumber of people with glaucoma worldwide.
Quigley, H. A. (1996) · British Journal of Ophthalmology · doi:10.1136/bjo.80.5.389 · Cited by 2,998 · cited 2×
“(Quigley, 1996) A 2006 review of worldwide glaucoma prevalence models estimated that by 2010 glaucoma would be the second leading overall cause of blindness in the world and leading cause of irreversible blindness, affecting 60.5 million people with prevalence varying worldwide(Quigley and Broman,…”
Influential(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Gordon, M. O. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.714 · Cited by 2,626
Social Indicators of Well-Being: Americans' Perceptions of Life Quality
Andrews, F. M., & Withey, S. B. (1976) · Medical Entomology and Zoology · Cited by 2,409
Factors for Glaucoma Progression and the Effect of Treatment: The Early Manifest Glaucoma Trial
Leske, M. C. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.48 · Cited by 2,030
(1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00223-2 · Cited by 1,599
Cited by
Neuroprotection in Glaucoma: Animal Models and Clinical Trials
Almasieh, M., & Levin, L. A. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061422 · Cited by 111
Self-citation
Metadata
- Authors
- De Moraes, C. G., Liebmann, J. M., & Levin, L. A.
- Venue
- Progress in Retinal and Eye Research
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 56
- Pages
- 107-147
- ISSN
- 1350-9462 (ISSN-L)
- OpenAlex
- W2538869024
- Cited by
- 203
- References
- 82
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.